{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:39:26Z","timestamp":1777876766949,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"ministero della salute","doi-asserted-by":"publisher","award":["RC-2024-2790047"],"award-info":[{"award-number":["RC-2024-2790047"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recent advances in understanding the biology of cancer have resulted in an extensive armamentarium of new therapeutic agents, most often tested on various tumor types at the earliest stages of drug development. However, the clinical impact of these therapies on patients with head and neck cancer (HNC) remains underexplored and requires further evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate the clinical outcomes and toxicity profiles of patients with HNC enrolled in phase I trials (Ph1t) at a tertiary referral center over the last decade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted, analyzing data from HNC patients enrolled in phase I trials at the Curie Institute between October 2011 and January 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data on baseline characteristics, hematologic biomarkers, and outcomes were extracted from medical records. Objective response rate (ORR) and Kaplan\u2013Meier estimates of progression-free survival (PFS) and overall survival (OS) were analyzed. A Cox model was used for the identification of prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred and thirty patients were enrolled in Ph1t for recurrent\/metastatic (R\/M) setting (66.9%), including 20.8% of patients being treated with more than two lines of therapy, followed by locally advanced (LA) treated with radical surgery or exclusive chemo\/radiotherapy (17.7%), neoadjuvant (10.0%), and adjuvant (5.4%) Ph1t. Patients were treated with immunotherapy (53.8%), targeted therapy (23.1%), bispecific antibody (8.5%), antibody\u2013drug conjugate (4.6%), and other agents (10.0%). In 122 patients evaluable for response, ORR were 16.5%, 87.0%, and 92.3% in R\/M, LA, and neoadjuvant Ph1t, respectively. Median PFS\/OS rates were 2.0\/8.3, 21.5\/38.3, and 20.0\/27.4\u2009months in R\/M, LA, and neoadjuvant Ph1t, respectively.<\/jats:p>\n                    <jats:p>\n                      At multivariable analysis, lower lymphocytes (HR\u2009=\u20090.144; 95% CI: 0.052\u20130.399;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and lower albumin levels (HR\u2009=\u20090.922; 95% CI: 0.879\u20130.966;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) remained associated with poorer OS. Grade 3\u20134 adverse events were recorded in 27\/130 patients (20.8%). The most frequent were hematologic and gastrointestinal disorders. No treatment-related deaths occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HNC Ph1t show encouraging results in terms of early efficacy signals and safety profiles, emphasizing their value across a variety of clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251337244","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:51:50Z","timestamp":1754985110000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical landscape for patients with head and neck cancers enrolled in phase I trials at a tertiary referral center"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-7282","authenticated-orcid":false,"given":"Daria Maria","family":"Filippini","sequence":"first","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Bastien","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Jacquin","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandro","family":"Paccapelo","sequence":"additional","affiliation":[{"name":"Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2660-7381","authenticated-orcid":false,"given":"Caroline","family":"Nhy","sequence":"additional","affiliation":[{"name":"Radiology Department, Institut Curie Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Klijanienko","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Curie, PSL Research University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Calugaru","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Chilles","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4046-7789","authenticated-orcid":false,"given":"Wahib","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Rougier","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Dubray Vautrin","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Badois","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lesnik","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Choussy","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Paule","family":"Sablin","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"},{"name":"INSERM U900 Research Unit, Saint-Cloud, France"},{"name":"Paris-Saclay University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010240"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02903"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9606"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp079"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057716"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803837"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.23"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"e_1_3_5_16_2","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata statistical software: release 18. College Station, TX: StataCorp LLC, 2023."},{"issue":"9658","key":"e_1_3_5_17_2","first-page":"989","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"373","author":"Pignon JP","year":"2009","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Lancet 2009; 373(9658): 989\u20131000.","journal-title":"Lancet"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.07.005"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/coa.13316"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01390-3"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03992-2"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4692"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2021.00062"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0395-x"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25075"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.10.027"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092456"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03522-2"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco-24-33"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251337244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251337244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251337244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:11Z","timestamp":1777588331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251337244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"alternative-id":["10.1177\/17588359251337244"],"URL":"https:\/\/doi.org\/10.1177\/17588359251337244","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"17588359251337244"}}